NCT02762981View on ClinicalTrials.gov

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

May 23, 2016

Primary Completion Date

May 12, 2020

Study Completion Date

September 12, 2020

Conditions
Solid Tumors
Interventions
DRUG

Relacorilant with nab-paclitaxel

Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.

Trial Locations (4)

60637

001, Chicago

84403

013, Ogden

85258

038, Scottsdale

94143

014, San Francisco

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY